Darren R Feldman1, Anja Lorch1, Andrew Kramar1, Costantine Albany1, Lawrence H Einhorn1, Patrizia Giannatempo1, Andrea Necchi1, Aude Flechon1, Helen Boyle1, Peter Chung1, Robert A Huddart1, Carsten Bokemeyer1, Alexey Tryakin1, Teodoro Sava1, Eric William Winquist1, Ugo De Giorgi1, Jorge Aparicio1, Christopher J Sweeney1, Gabriella Cohn Cedermark1, Jörg Beyer2, Thomas Powles1. 1. Darren R. Feldman, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY; Anja Lorch, University Hospital Düsseldorf, Düsseldorf; Carsten Bokemeyer, University Hospital Eppendorf, Hamburg, Germany; Andrew Kramar, Centre Oscar Lambret, Lille; Aude Flechon and Helen Boyle, Centre Léon Bérard, Lyon, France; Costantine Albany and Lawrence H. Einhorn, Indiana University, Bloomington, IN; Patrizia Giannatempo and Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milano; Teodoro Sava, Azienda Ospedaliera Universitaria Integrata di Verona, Verona; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy; Peter Chung, Princess Margaret Cancer Centre, University of Toronto, Toronto; Eric William Winquist, London Health Sciences Center, London, Ontario, Canada; Robert A. Huddart, Royal Marsden Hospital; Thomas Powles, St Bartholomew's Hospital, London, United Kingdom; Alexey Tryakin, Blokhin's Russian Cancer Research Center, Moscow, Russia; Jorge Aparicio, University Hospital Le Fe, Valencia, Spain; Christopher J. Sweeney, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; and Jörg Beyer, UniversitätsSpital Zürich, Zürich, Switzerland. 2. Darren R. Feldman, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY; Anja Lorch, University Hospital Düsseldorf, Düsseldorf; Carsten Bokemeyer, University Hospital Eppendorf, Hamburg, Germany; Andrew Kramar, Centre Oscar Lambret, Lille; Aude Flechon and Helen Boyle, Centre Léon Bérard, Lyon, France; Costantine Albany and Lawrence H. Einhorn, Indiana University, Bloomington, IN; Patrizia Giannatempo and Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milano; Teodoro Sava, Azienda Ospedaliera Universitaria Integrata di Verona, Verona; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy; Peter Chung, Princess Margaret Cancer Centre, University of Toronto, Toronto; Eric William Winquist, London Health Sciences Center, London, Ontario, Canada; Robert A. Huddart, Royal Marsden Hospital; Thomas Powles, St Bartholomew's Hospital, London, United Kingdom; Alexey Tryakin, Blokhin's Russian Cancer Research Center, Moscow, Russia; Jorge Aparicio, University Hospital Le Fe, Valencia, Spain; Christopher J. Sweeney, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; and Jörg Beyer, UniversitätsSpital Zürich, Zürich, Switzerland. joerg.beyer@usz.ch.
Abstract
PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT). PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point. RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001). CONCLUSION: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.
PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT). PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point. RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001). CONCLUSION:Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.
Authors: C Bokemeyer; P Nowak; A Haupt; B Metzner; H Köhne; J T Hartmann; L Kanz; H J Schmoll Journal: J Clin Oncol Date: 1997-04 Impact factor: 44.544
Authors: C Kollmannsberger; C Nichols; M Bamberg; J T Hartmann; N Schleucher; J Beyer; P Schöfski; G Derigs; U Rüther; I Böhlke; H J Schmoll; L Kanz; C Bokemeyer Journal: Ann Oncol Date: 2000-05 Impact factor: 32.976
Authors: R Girones; J Aparicio; P Roure; J R Germa-Lluch; X García Del Muro; S Vazquez-Estevez; A Saenz; J Sastre; J Arranz Arija; E Gallardo; E Gonzalez-Billalabeitia; A Sanchez-Hernandez; J Terrasa; A Hernandez; C Santander; E Cillan; N Sagastibelza; D Almenar-Cubells; M Lopez Brea; J P Maroto Journal: Clin Transl Oncol Date: 2014-04-10 Impact factor: 3.405
Authors: Anja Lorch; Jörg Beyer; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence H Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim A Margolin; Jean-Pierre Lotz; Jose Ramon Germa Lluch; Thomas Powles; Christian K Kollmannsberger Journal: J Clin Oncol Date: 2010-10-18 Impact factor: 44.544
Authors: J Beyer; P Albers; R Altena; J Aparicio; C Bokemeyer; J Busch; R Cathomas; E Cavallin-Stahl; N W Clarke; J Claßen; G Cohn-Cedermark; A A Dahl; G Daugaard; U De Giorgi; M De Santis; M De Wit; R De Wit; K P Dieckmann; M Fenner; K Fizazi; A Flechon; S D Fossa; J R Germá Lluch; J A Gietema; S Gillessen; A Giwercman; J T Hartmann; A Heidenreich; M Hentrich; F Honecker; A Horwich; R A Huddart; S Kliesch; C Kollmannsberger; S Krege; M P Laguna; L H J Looijenga; A Lorch; J P Lotz; F Mayer; A Necchi; N Nicolai; J Nuver; K Oechsle; J Oldenburg; J W Oosterhuis; T Powles; E Rajpert-De Meyts; O Rick; G Rosti; R Salvioni; M Schrader; S Schweyer; F Sedlmayer; A Sohaib; R Souchon; T Tandstad; C Winter; C Wittekind Journal: Ann Oncol Date: 2012-11-14 Impact factor: 32.976
Authors: Dana L Casey; Kenneth L Pitter; Brandon S Imber; Andrew Lin; Timothy A Chan; Kathryn Beal; Yoshiya Yamada; Darren R Feldman; T Jonathan Yang Journal: J Neurooncol Date: 2019-02-15 Impact factor: 4.130
Authors: Hiten D Patel; Nirmish Singla; Rashed A Ghandour; Yuval Freifeld; Joseph G Cheaib; Solomon L Woldu; Phillip M Pierorazio; Aditya Bagrodia Journal: Cancer Date: 2019-07-29 Impact factor: 6.860
Authors: Robert J Hamilton; Christina Canil; Noa Shani Shrem; Kopika Kuhathaas; Maria Di Jiang; Peter Chung; Scott North; Piotr Czaykowski; Sebastien Hotte; Eric Winquist; Christian Kollmannsberger; Armen Aprikian; Denis Soulières; Scott Tyldesley; Alan I So; Nicholas Power; Ricardo A Rendon; Martin O'Malley; Lori Wood; Michael A S Jewett Journal: Can Urol Assoc J Date: 2022-06 Impact factor: 2.052
Authors: Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga Journal: Nat Rev Dis Primers Date: 2018-10-05 Impact factor: 52.329
Authors: J Aparicio; J Terrasa; I Durán; J R Germà-Lluch; R Gironés; E González-Billalabeitia; J Gumà; P Maroto; A Pinto; X García-Del-Muro Journal: Clin Transl Oncol Date: 2016-11-04 Impact factor: 3.405